Cubicin Endocarditis Trial Shows Improved Renal Safety Over Vancomycin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pivotal data for Cubist's Cubicin treatment of endocarditis/bacteremia show comparable efficacy to standard care with superior renal safety, the firm reported Dec. 16